Advertisement

Diabetologia

, Volume 35, Issue 2, pp 116–120 | Cite as

Effects of islet amyloid polypeptide on hepatic insulin resistance and glucose production in the isolated perfused rat liver

  • M. Roden
  • K. Liener
  • C. Fürnsinn
  • P. Nowotny
  • U. Hollenstein
  • H. Vierhapper
  • W. Waldhäusl
Originals

Summary

The impact of (pancreatic) islet amyloid polypeptide on glucose metabolism and insulin sensitivity was examined in isolated rat livers perfused in a non-recirculating system. Continuous infusion of 10−7mol/l islet amyloid polypeptide affected neither basal nor glucagon (10−9 mol/l)-stimulated glucose output by livers from fed rats, but it did increase the hepatic cyclic AMP release within 44 min (7.91±12.07 vs control: 0.07±0.03 pmol·100 g body weight−1). The effect of the peptide on the ability of insulin to inhibit glucagon-induced hepatic glycogenolysis was measured in three experimental groups (n = 6). As expected glucagon (7×10−11 mol/l) increased integral hepatic glucose release within 84 min (763.4±161.7 vs −25.7±73.2 μmol · 100 g body weight−1 in the control group, p<0.001), while insulin (100 mU/l) decreased the glucagon-stimulated glucose production (395.2±180.0 μmol·100 g body weight−1, p<0.01). Simultaneous infusion of 10−7 mol/l islet amyloid polypeptide however, was not able to reverse insulin-dependent inhibition of glucagon-stimulated hepatic glucose output (370.0±102.5 μmol·100 g body weight−1, NS) or to enhance lactate-induced gluconeogenesis of livers from 24 h fasted rats (n = 8). The glucose production stimulated by 10−9 mol/l glucagon was slightly greater in islet amyloid polypeptide-pre-treated livers than in a control group without addition of islet amyloid polypeptide (5 min: 3.60±3.36 vs 1.67±1.28 μmol·min−1·100 g body weight−1). These results suggest that islet amyloid polypeptide neither directly affects hepatic glycogenolysis nor causes insulin resistance to hormone-sensitive glucose production, but may increase the size of the hepatic glycogen pool by enhancing gluconeogenesis.

Key words

Isolated liver perfusion insulin resistance islet amyloid polypeptide 

References

  1. 1.
    DeFronzo RA (1987) Lilly lecture 1987: The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM. Diabetes 37: 667–687Google Scholar
  2. 2.
    Olefsky JM (1980) Insulin resistance and insulin action. An in vitro and in vivo perspective. Diabetes 30: 148–162Google Scholar
  3. 3.
    Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84: 3881–3885PubMedGoogle Scholar
  4. 4.
    Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628–8632PubMedGoogle Scholar
  5. 5.
    Johnson KH, O'Brien TD, Hayden DW et al. (1988) Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 130: 1–8PubMedGoogle Scholar
  6. 6.
    Leffert JD, Newgard CB, Okamoto H, Milburn JL, Luskey KL (1989) Rat amylin cloning and tissue-specific expression in pancreatic islets. Proc Natl Acad Sci USA 86: 3127–3130PubMedGoogle Scholar
  7. 7.
    Kahn SE, D'Alessio DA, Schwartz MW et al. (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39: 634–638PubMedGoogle Scholar
  8. 8.
    Nakazato M, Asai J, Kanagawa K, Sakakibara S, Matsukura S, Matsuo H (1989) Establishment of radioimmunoassay for human islet amyloid polypeptide and its tissue content and plasma concentration. Biochem Biophys Res Commun 164: 394–399PubMedGoogle Scholar
  9. 9.
    Leighton B, Cooper GJS (1988) Pancreatic amylin and calcitonin-gene related peptide cause resistance to insulin in skeletal muscle in vitro. Nature (London) 335: 632–635Google Scholar
  10. 10.
    Cooper GJS, Leighton B, Dimitriadis GD et al. (1988) Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 85: 7763–7766PubMedGoogle Scholar
  11. 11.
    Sowa R, Sanke T, Hirayama J et al. (1990) Islet amyloid polypeptide amide causes peripheral insulin resistance in vivo in dogs. Diabetologia 33: 118–120PubMedGoogle Scholar
  12. 12.
    Molina JM, Cooper GJS, Leighton B, Olefsky JM (1990) Induction of insulin resistance in vivo by amylin and calcitonin gene-related peptide. Diabetes 39: 260–265PubMedGoogle Scholar
  13. 13.
    Ciaraldi TP, Cooper GJS, Stolpe M (1990) In vitro effects of amylin on carbohydrate metabolism. Diabetes 39: 149A (Abstract)Google Scholar
  14. 14.
    Young DA, Deems RO, Deacon RW, McIntosh RH, Foley JE (1990) Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol: E457–E461Google Scholar
  15. 15.
    Komjati M, Bratusch-Marrain P, Waldhäusl W (1986) Superior efficacy of pulsatile versus continuous hormone exposure on hepatic glucose production in vitro. Endocrinology 118: 312–319PubMedGoogle Scholar
  16. 16.
    Exton JH, Park CR (1967) Control of gluconeogenesis in liver. I. General features of gluconeogenesis in the perfused livers of rats. J Biol Chem 242: 2622–2636PubMedGoogle Scholar
  17. 17.
    SAS User's Guide (1982) Statistics. SAS Institute, CaryGoogle Scholar
  18. 18.
    Morishita T, Yamaguchi A, Fujita T, Chiba T (1990) Activation of adenylate cyclase by islet amyloid polypeptide with COOH-terminal amide via calcitonin gene-related peptide receptors on rat liver plasma membranes. Diabetes 39: 875–877PubMedGoogle Scholar
  19. 19.
    Exton JH, Lewis SB, Ho RJ, Robinson GA, Park CR (1971) The role of cyclic AMP in the interaction of glucagon and insulin in the control of liver metabolism. Ann NY Acad Sci 185: 85–100PubMedGoogle Scholar
  20. 20.
    Sutherland EW, Rall TW (1958) Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem 232: 1077–1091PubMedGoogle Scholar
  21. 21.
    Stephens TW, Heath WF, Hermeling RN (1991) Presence of liver CGRP/Amylin receptors in only nonparenchymal cells and absence of direct regulation of rat liver glucose metabolism by CGRP/Amylin. Diabetes 40: 395–400PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • M. Roden
    • 1
  • K. Liener
    • 1
  • C. Fürnsinn
    • 1
  • P. Nowotny
    • 1
  • U. Hollenstein
    • 1
  • H. Vierhapper
    • 1
  • W. Waldhäusl
    • 1
  1. 1.Ist Medical Department, Division of Clinical Endocrinology and DiabetologyUniversity of ViennaAustria

Personalised recommendations